We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Synthetic Graft Expedites the Repair of Bone Defects

By HospiMedica International staff writers
Posted on 10 Nov 2010
An easy-to-produce, inexpensive, synthetic bone material could be a potential replacement for current bone transplantations.

Developed by researchers at the University of Massachusetts (UMass; Worcester, USA), FlexBone is a nanocrystalline hydroxyapatite structurally integrated with a crosslinked Poly[2-hydroxyethyl methacrylate] (pHEMA)hydrogel, which provides dimensional stability and elasticity. More...
It recapitulates the essential role of nanocrystalline hydroxyapatite in defining the osteoconductivity and biochemical microenvironment of bone, due to its affinity for biomolecules. FlexBone has a bone mineral content approaching that of human bone, enabling the elastic material to be cut and shaped prior to surgery or intra-operatively, and then pressed into a bone gap.

The density of the material also allows surgeons to pre-drill channels in it, allowing for bone marrow from adjacent bone to migrate and penetrate, thus attracting progenitor cells that are critical to new bone formation. FlexBone absorbs and retains the proteins associated with the natural healing process from the surrounding tissue once implanted; it can also be loaded with therapeutic agents, such as protein factors and antibiotics that can facilitate faster healing and fight infection through localized and controlled delivery over a sustained period of time. The study describing Flexbone was published ahead of print on October 21, 2010, in Tissue Engineering Part A.

"Because of this combination of factors, our study shows that FlexBone, combined with a protein growth factor in a dose 100 times less than what currently needed, was able to heal a large, long bone defect that would not heal on its own in a short period of time,” said lead author Jie Song, Ph.D., an assistant professor of orthopedics, physical rehabilitation, and cell biology. "This material has enormous potential to solve a major problem that orthopedic surgeons face when reconstructing large bone deficits in the skeleton.”

Related Links:
University of Massachusetts



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.